학술논문
1190 A novel ‘2+1’bispecific T cell engager platform, enables enhanced anti-tumor activity with reduced risk of CRS
Document Type
article
Author
Source
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Subject
Language
English
ISSN
2051-1426